Market Cap | 223.97M | P/E | - | EPS this Y | 17.60% | Ern Qtrly Grth | - |
Income | -87.98M | Forward P/E | -1.79 | EPS next Y | 57.10% | 50D Avg Chg | -11.00% |
Sales | - | PEG | 0.01 | EPS past 5Y | - | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | 0.93 | EPS next 5Y | -28.90% | 52W High Chg | -36.00% |
Recommedations | 3.00 | Quick Ratio | 9.91 | Shares Outstanding | 108.06M | 52W Low Chg | 95.00% |
Insider Own | 5.91% | ROA | -21.67% | Shares Float | 25.38M | Beta | 0.23 |
Inst Own | 78.99% | ROE | -32.42% | Shares Shorted/Prior | 378.13K/232.75K | Price | 2.09 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 267,550 | Target Price | 3.90 |
Oper. Margin | - | Earnings Date | Mar 25 | Volume | 2,598,609 | Change | 5.56% |
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
B of A Securities | Underperform | Jan 3, 24 |
Jefferies | Hold | Dec 22, 23 |
Raymond James | Outperform | Oct 25, 23 |
Raymond James | Outperform | Oct 14, 22 |
Goldman Sachs | Neutral | Nov 26, 21 |
Jefferies | Buy | Nov 26, 21 |
Raymond James | Outperform | Nov 24, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
PERCEPTIVE ADVISORS LLC | Director Director | Aug 18 | Buy | 2.40 | 998,240 | 2,395,776 | 3,728,491 | 08/22/22 |
PERCEPTIVE ADVISORS LLC | Director Director | May 26 | Buy | 3.13 | 69,000 | 215,970 | 2,730,251 | 05/27/22 |
PERCEPTIVE ADVISORS LLC | Director Director | May 23 | Buy | 2.53 | 171,251 | 433,265 | 2,661,251 | 05/25/22 |
PERCEPTIVE ADVISORS LLC | Director Director | Nov 01 | Buy | 14.5 | 220,000 | 3,190,000 | 7,253,885 | 11/03/21 |